[go: up one dir, main page]

WO1998000119A3 - Applications of active substances affecting the functions of non neuronal acetylcholine - Google Patents

Applications of active substances affecting the functions of non neuronal acetylcholine Download PDF

Info

Publication number
WO1998000119A3
WO1998000119A3 PCT/EP1997/003415 EP9703415W WO9800119A3 WO 1998000119 A3 WO1998000119 A3 WO 1998000119A3 EP 9703415 W EP9703415 W EP 9703415W WO 9800119 A3 WO9800119 A3 WO 9800119A3
Authority
WO
WIPO (PCT)
Prior art keywords
applications
functions
neuronal acetylcholine
active substances
non neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/003415
Other languages
German (de)
French (fr)
Other versions
WO1998000119A2 (en
Inventor
Ignaz Wessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to AU32632/97A priority Critical patent/AU3263297A/en
Publication of WO1998000119A2 publication Critical patent/WO1998000119A2/en
Publication of WO1998000119A3 publication Critical patent/WO1998000119A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a process for determining the functional state of non-neuronal acetylcholine in human tissue or cells which are accessible either directly or by endoscopy. It also relates to the use of active ingredients which can affect the synthesis, release, inactivation and function of non-neuronal acetylcholine.
PCT/EP1997/003415 1996-07-02 1997-07-01 Applications of active substances affecting the functions of non neuronal acetylcholine Ceased WO1998000119A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32632/97A AU3263297A (en) 1996-07-02 1997-07-01 New use of active ingredients which affect non-neuronal acetylcholine functions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19626373.5 1996-07-02
DE19626373A DE19626373A1 (en) 1996-07-02 1996-07-02 Novel use of active ingredients that affect the function of non-neuronal acetylcholine

Publications (2)

Publication Number Publication Date
WO1998000119A2 WO1998000119A2 (en) 1998-01-08
WO1998000119A3 true WO1998000119A3 (en) 1998-04-02

Family

ID=7798569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/003415 Ceased WO1998000119A2 (en) 1996-07-02 1997-07-01 Applications of active substances affecting the functions of non neuronal acetylcholine

Country Status (4)

Country Link
AU (1) AU3263297A (en)
DE (1) DE19626373A1 (en)
WO (1) WO1998000119A2 (en)
ZA (1) ZA975804B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008672A1 (en) * 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
GB9918760D0 (en) * 1999-08-09 1999-10-13 Darwin Discovery Ltd Topical treatment
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
DE10111843A1 (en) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
EP1481689A4 (en) * 2002-02-07 2005-10-05 Eisai Co Ltd Hair growth stimulants, percutaneous preparations and method of stimulating hair growth
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
GB2419093A (en) * 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
EP2008660A1 (en) * 2004-10-12 2008-12-31 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
WO2014140647A1 (en) 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
AU2017264119A1 (en) * 2016-05-09 2018-12-06 Nanoegg Research Laboratories, Inc. Composition for treating or preventing atopic dermatitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1243729A1 (en) * 1984-06-01 1986-07-15 Киевский государственный институт усовершенствования врачей Method of treatment of neurodermite
US5084281A (en) * 1989-02-14 1992-01-28 Dillon Richard S Method and solution for treating tissue wounds
EP0534343A1 (en) * 1991-09-23 1993-03-31 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1H-indoles, 1H-indazoles, 2H-indazoles, benzo(b) thiophenes and 1,2-benzisothiazoles, a process for their preparation and their use as medicaments
WO1994015623A1 (en) * 1992-12-30 1994-07-21 Patent Biopharmaceutics Inc. Hyaluronic acid-urea pharmaceutical compositions and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1243729A1 (en) * 1984-06-01 1986-07-15 Киевский государственный институт усовершенствования врачей Method of treatment of neurodermite
US5084281A (en) * 1989-02-14 1992-01-28 Dillon Richard S Method and solution for treating tissue wounds
EP0534343A1 (en) * 1991-09-23 1993-03-31 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1H-indoles, 1H-indazoles, 2H-indazoles, benzo(b) thiophenes and 1,2-benzisothiazoles, a process for their preparation and their use as medicaments
WO1994015623A1 (en) * 1992-12-30 1994-07-21 Patent Biopharmaceutics Inc. Hyaluronic acid-urea pharmaceutical compositions and uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE Dialog Information Services; XP002047242 *
DATABASE WPI Section Ch Week 8710, Derwent World Patents Index; Class B05, AN 87-071007, XP002047243 *
EVANS S. ET AL: "Synthesis and release of acetylcholine in the rabbit kidney cortex", LIFE SCI. (ENGLAND), vol. 51, no. 22, 1992, pages 1699 - 1703, XP002047239 *
GAJEWAKI W.: "Disappeareance of psoriatic skin rashes in the course of atropine therapy", POL TYG LEK, vol. 25, no. 47, November 1970 (1970-11-01), pages 1815 - 1816 *
KLAPPROTH H. ET AL: "Non-neuronal acetylcholine, a signalling molecule synthezised by surface cells of rat and man", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 355, no. 4, April 1997 (1997-04-01), pages 515 - 523, XP002047241 *
KLAPPROTH H. ET AL: "Non-neuronal acetylcholine, a widespread signalling molecule in man", BRITISH JOURNAL OF PHARMACOLOGY, vol. 120, March 1997 (1997-03-01), pages 61P, XP002047240 *
REINHEIMER T. ET AL: "Acetylcholine in isolated airways of rat, guinea pig, and human: species differences in role of airway mucosa", AM. J. PHYSIOL. (UNITED STATES), vol. 14, no. 5, May 1996 (1996-05-01), pages L722 - L728, XP002047238 *

Also Published As

Publication number Publication date
AU3263297A (en) 1998-01-21
WO1998000119A2 (en) 1998-01-08
ZA975804B (en) 1998-01-02
DE19626373A1 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
CA2180950A1 (en) Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
AU3689595A (en) Device for use in the laser treatment of biological tissue (variants thereof)
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
AU4075195A (en) Instrumentation for use in orthopaedic surgery
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
DE69638351D1 (en) AS WELL AS FOR RESISTING THE DISTAL AND FRONT FEMUR
WO1996028008A3 (en) Novel cosmetic or dermatological compositions for controlling skin ageing
EP2213302A3 (en) DR4 antibodies and uses thereof
CA2132369A1 (en) Use for the Treatment of Mixed Skins, of an Effective Quantity of Active Substances
AU2080697A (en) Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
MX9710252A (en) Use of one or more peptides in a cosmetic composition or for the preparation of a medicament.
WO1998000119A3 (en) Applications of active substances affecting the functions of non neuronal acetylcholine
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
WO2001045650A3 (en) Cosmetic use of the residues from wine production
HRP970292B1 (en) Substituted 2-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
AU5539798A (en) Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
CA2322027A1 (en) Use of macrolide compounds for the treatment of ards
AU4994996A (en) Composition for the treatment of diarrhea, its use and its preparation
HU9701316D0 (en) Substituted indanylideneacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
AU2593597A (en) Compositions for the diagnosis and treatment of chediak-higashi syndrome
WO1999045894A3 (en) Cosmetic compositions
AU2001296477A1 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
NZ514691A (en) Method to type prion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CN CZ EE HU IL JP KR KZ LT LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CN CZ EE HU IL JP KR KZ LT LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97532940

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase